LTI
2.8.2022 11:02:08 CEST | Business Wire | Press release
Larsen & Toubro Infotech (BSE: 540005, NSE: LTI ), a global technology consulting and digital solutions company, has announced the expansion of its collaboration with Microsoft to focus on developing high-value cloud solutions for enterprises. As a part of this multi-year collaboration, LTI has launched a dedicated Microsoft business unit that develops and offers end-to-end digital transformation solutions.
Through this association, LTI will also train 12,000 professionals from its existing workforce on various Microsoft technologies by 2024. The main objective of this effort is to enable skill development of LTI employees that are a part of the Microsoft unit and enhance their competencies across technologies like cloud, data, IoT and security.
Nachiket Deshpande, Chief Operating Officer, LTI, said, “LTI has a long-standing relationship with Microsoft as a strategic partner, service provider, and customer. Our reaffirmed partnership with Microsoft will enable us to innovate and offer 170+ distinct services to our joint customers. Additionally, we will also focus on the training and upskilling of our talent pool that is a part of the dedicated Microsoft business unit, to empower them to meet changing business and market requirements.”
Siddharth Bohra, Chief Business Officer & Head of Cloud Business Unit, LTI , said, “Enterprises across the globe are increasingly embracing cloud, and LTI has made impressive strides in developing a multi-dimensional capability on Azure to meet this demand. As part of this collaboration, LTI and Microsoft will jointly innovate, develop, and sell solutions to assist enterprises in acceleration of their digital transformation journeys.”
Julie Sanford, Vice President, Partner GTM, Programs & Experiences, Microsoft , said, “Through their new Microsoft Business Unit, LTI will be able to help customers implement cloud strategies and drive business transformation across industries and geographies. We look forward to working with LTI as they build new capabilities and deliver innovative solutions on the Microsoft Cloud.”
Through this association, LTI will attain the Solution Partner designation across all the Microsoft Solution Areas. LTI also has the following advanced specializations on Azure:
- SAP on Azure : Validating the capability of implementing SAP solutions on Azure.
- Analytics on Azure : Demonstrating the expertise in delivering analytics solutions in Microsoft Azure.
- Windows Server and SQL Server : Expertise in migrating production workloads to Microsoft Azure.
- Modernization of Web Applications : Validating expertise in migrating and deploying production web application workloads, applying DevOps, and managing app services in Microsoft Azure.
- Kubernetes on Azure : validating capabilities in deploying and managing production workloads in the cloud using containers and managing hosted Kubernetes environments in Azure.
- Low Code Application Development : Expertise in building solutions using Power Apps.
- The Data Warehouse Migration to Microsoft Azure : Validating expertise in analyzing existing workloads and performing ETL operations to migrate data to cloud-based data warehouses.
- Cloud Security : Validates a means for your company to showcase capabilities to implement comprehensive security solutions across Azure, hybrid, and multi-cloud environments.
- Threat Protection : provides a means for your company to showcase proven, verifiable expertise in deploying Microsoft Threat Protection or Microsoft Cloud App Security workloads.
- AI and Machine Learning in Microsoft Azure : Validates capabilities on enabling customer adoption of Al and implementing Azure solutions for Al-powered apps.
LTI is an Azure Expert MSP Partner which demonstrates deep knowledge, extensive experience, and proven success in implementing specialized workloads such as Migration and Modernization, SAP on Azure, Data Analytics, Internet of things (IoT), Security, and Microsoft Dynamics 365.
About LTI:
LTI (NSE: LTI ) is a global technology consulting and digital solutions Company helping more than 495 clients succeed in a converging world. With operations in 33 countries, we go the extra mile for our clients and accelerate their digital transformation journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 46,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees, and shareholders. Find more at https://www.lntinfotech.com or follow us at @LTI_Global .
Connect with LTI:
Read More:
- LTI Becomes Microsoft Azure Expert Managed Services Provider
- LTI has Earned the Kubernetes on Microsoft Azure Advanced Specialization
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005516/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom